Experienced in Cholangiocarcinoma (Bile Duct Cancer)

Kazuhito Kawata

Hamamatsu, JP 
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Hamamatsu, JP 
OverviewLocationsClinical Research

Overview

Kazuhito Kawata practices in Hamamatsu, Japan. Kawata is rated as an Experienced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Their top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Liver Cancer, Endoscopy, and Liver Embolization.

Their clinical research consists of co-authoring 164 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Locations

Hamamatsu, Japan
Other Locations
Kashiwa, 2778582, Japan
Osaka, Japan
Toyonaka, 5600043, Japan
Higashi, Japan
Tokai, Japan
Wako, 3510198, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drug: Linerixibat
Study Phase: Phase 3

164 Total Publications

Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kawata's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile